Mounjaro vs Zepbound: Why the Same Drug Has Two Names

Yes. Both Mounjaro and Zepbound are brand names for tirzepatide, a once-weekly injectable made by Eli Lilly. They share identical molecules, identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), and identical titration schedules. The only physical difference is the labeling on the pen. Lilly created two separate brands so that the diabetes and obesity indications could be marketed, priced, and covered separately by insurers. Pharmacies dispense whichever brand is written on your prescription, and you cannot legally substitute one for the other at the counter even though the contents are identical.

Mounjaro received FDA approval in May 2022 for adults with type 2 diabetes, alongside diet and exercise, to improve blood sugar control. Zepbound was approved in November 2023 for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) who have a weight-related condition like high blood pressure or sleep apnea. In December 2024, the FDA expanded Zepbound's label to include moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. Mounjaro does not carry these obesity indications, even though the drug works the same way in the body.

Across the SURMOUNT-1 trial, adults without diabetes lost an average of 22.5% of body weight at the highest dose over 72 weeks. SURMOUNT-3 paired tirzepatide with intensive lifestyle intervention and produced even higher losses. SURMOUNT-5, the head-to-head trial against semaglutide (Wegovy), showed tirzepatide produced about 47% more weight loss than semaglutide over 72 weeks. Because Mounjaro and Zepbound contain the same drug, the same efficacy data applies to both. The choice between brand names is administrative, not clinical.

Most commercial insurance plans cover Mounjaro when you have a type 2 diabetes diagnosis, often with a $25 to $50 monthly copay after savings cards. Coverage for Zepbound is narrower: many plans either exclude weight-loss medications outright or require prior authorization, BMI documentation, and proof of a supervised lifestyle program. Without insurance, the brand-name pens of either medication carry a list price near $1,000 per month. Eli Lilly's LillyDirect program now sells single-dose Zepbound vials (you draw the dose with a syringe) at lower self-pay prices: roughly $349 for 2.5 mg, $499 for 5 mg, and $599 for 7.5 mg as of early 2026. There is no equivalent vial program for Mounjaro.

Clinically, switching is seamless because the drug is identical. Practically, you need a new prescription written with the correct indication. If you started on Mounjaro for prediabetes or diabetes and you also want to address obesity, your prescriber can transition you to Zepbound at the same dose. Patients sometimes switch when their diabetes coverage ends, when a job change shifts their insurance, or when they want access to Lilly's vial pricing. Always coordinate with your prescriber and pharmacy so there is no gap in dosing, since pausing tirzepatide tends to bring back appetite and food noise quickly.

The most common side effects with both Mounjaro and Zepbound are gastrointestinal: nausea, diarrhea, vomiting, constipation, and indigestion. These are usually worst right after each dose increase and improve as the body adapts. Less common but more serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and a boxed warning about thyroid C-cell tumors based on rodent studies. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take tirzepatide. Talk with your healthcare provider about your full history before starting.

If your primary diagnosis is type 2 diabetes, Mounjaro is the right starting conversation because it is on-label and easier to get covered. If your goal is weight loss or you have sleep apnea with obesity, Zepbound is the on-label option and is required for legitimate obesity coverage and for the LillyDirect vial program. Some patients qualify for both indications; in that case, your prescriber chooses the brand based on which indication your insurance is more likely to cover. Either way, the molecule entering your body is the same.